TW239131B - - Google Patents
Info
- Publication number
- TW239131B TW239131B TW082106302A TW82106302A TW239131B TW 239131 B TW239131 B TW 239131B TW 082106302 A TW082106302 A TW 082106302A TW 82106302 A TW82106302 A TW 82106302A TW 239131 B TW239131 B TW 239131B
- Authority
- TW
- Taiwan
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/926,795 US5310929A (en) | 1992-08-06 | 1992-08-06 | Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW239131B true TW239131B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1995-01-21 |
Family
ID=25453732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW082106302A TW239131B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-08-06 | 1993-08-06 |
Country Status (18)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5616599A (en) * | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
| CA2111662C (en) * | 1992-12-17 | 2004-11-23 | Hiroaki Yanagisawa | Biphenyl derivatives, their preparation and their use for the treatment of hypertension and cardiac disease |
| ATE206050T1 (de) * | 1994-03-16 | 2001-10-15 | Sankyo Co | Okulares hypotensium |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US5510495A (en) * | 1994-09-19 | 1996-04-23 | The Du Pont Merck Pharmaceutical Company | Process for the isolation and purification of ester functionalized imidazole intermediates by selective hydrolysis |
| DK0782996T3 (da) * | 1994-09-20 | 1999-09-20 | Wakunaga Seiyaku Kk | Fremgangsmåde til fremstilling af N-biphenylmethylthiadiazolinderivat eller salt deraf og mellemprodukt til fremstilling af |
| IT1292437B1 (it) * | 1997-06-30 | 1999-02-08 | Zambon Spa | Processo di orto-metallazione utile per la sintesi di 1 - tetrazol- 5-il) benzeni 2-sostituiti |
| IT1295405B1 (it) * | 1997-09-30 | 1999-05-12 | Merck Sharp & Dohme Italia S P | Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di |
| DE19820064A1 (de) * | 1998-05-06 | 1999-11-11 | Hoechst Marion Roussel De Gmbh | Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| DE19832428A1 (de) * | 1998-07-18 | 2000-01-20 | Hoechst Marion Roussel De Gmbh | Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19832429A1 (de) * | 1998-07-18 | 2000-01-20 | Hoechst Marion Roussel De Gmbh | Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| ES2154191B1 (es) * | 1998-11-24 | 2001-10-16 | Ferrer Int | Nuevos acetales derivados de los 2-alquil-5-halo-3-(2'-(tetrazol-5-il)-bifenil-4-ilmetil)-3h-imidazol-4-carbaldehidos. |
| GR20000100281A (el) * | 2000-08-17 | 2002-05-24 | Ιωαννης Ματσουκας | Ανταγωνιστες του υποδοχεα της αγγεοτενσινης ιι και συνθετικες μεθοδοι για την θεραπεια της υπερτασης και καρδιοαγγειακων ασθενειων |
| CN1529697B (zh) | 2001-05-31 | 2010-09-22 | 维科尔药物公司 | 用作血管紧张素ⅱ激动剂的三环化合物 |
| SI1509517T1 (sl) * | 2003-01-16 | 2008-10-31 | Teva Pharma | Nova sinteza irbesartana |
| WO2005068632A1 (ja) | 2004-01-20 | 2005-07-28 | Aichi Prefecture | ＨＬＡ−Ａ２４０２拘束性Ｅｐ−ＣＡＭ特異的ＣＴＬが認識するエピトープ・ペプチド及びその用途 |
| US7157584B2 (en) * | 2004-02-25 | 2007-01-02 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
| KR100953878B1 (ko) * | 2004-09-02 | 2010-04-22 | 테바 파마슈티컬 인더스트리즈 리미티드 | 올메살탄 메독소밀의 정제 |
| US20070054948A1 (en) * | 2004-09-02 | 2007-03-08 | Lilach Hedvati | Purification of olmesartan medoxomil |
| US20090123538A1 (en) * | 2005-04-20 | 2009-05-14 | Alani Laman L | Angiotensin II Receptor Antagonists |
| US20080103312A1 (en) * | 2006-08-29 | 2008-05-01 | Kansal Vinod K | Processes for the synthesis of 5-phenyl-1-trityl-1H-tetrazole |
| CA2663981C (en) * | 2006-10-09 | 2014-05-27 | Cipla Limited | Process for preparing trityl olmesartan medoxomil and olmesartan medoxomil |
| EP2103610B1 (en) * | 2006-12-06 | 2011-09-21 | Shanghai Allist Pharmaceutical., Inc. | Salts of imidazol-5-carboxylic acid derivatives, preparation methods and use thereof |
| CA2804034C (en) | 2010-01-07 | 2016-12-13 | Laura Cook Blumberg | Prodrugs of heteraromatic compounds |
| EP2455388A1 (en) | 2010-11-23 | 2012-05-23 | LanthioPep B.V. | Novel angiotensin type 2 (AT2) receptor agonists and uses thereof. |
| CN109320501B (zh) * | 2013-11-01 | 2021-06-01 | 深圳信立泰药业股份有限公司 | 阿利沙坦酯无定形及其制备方法及含所述无定形的药物组合物 |
| WO2021023698A1 (en) | 2019-08-02 | 2021-02-11 | Lanthiopep B.V | Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5138069A (en) * | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
| CA1338238C (en) * | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
| EP0479903B1 (en) * | 1989-06-30 | 1996-02-21 | E.I. Du Pont De Nemours And Company | Substituted imidazoles useful as angiotensin ii blockers |
| WO1991000281A2 (en) * | 1989-06-30 | 1991-01-10 | E.I. Du Pont De Nemours And Company | Fused-ring aryl substituted imidazoles |
| GB8927277D0 (en) * | 1989-12-01 | 1990-01-31 | Glaxo Group Ltd | Chemical compounds |
| US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| US5137902A (en) * | 1990-07-13 | 1992-08-11 | E. I. Du Pont De Nemours And Company | 4-alkylimidazole derivatives and anti-hypertensive use thereof |
| EP0573218B1 (en) * | 1992-06-02 | 2001-03-07 | Sankyo Company Limited | 4-Carboxyimidazoles as angiotensin II antagonists and their thrapeutic use |
-
1992
- 1992-08-06 US US07/926,795 patent/US5310929A/en not_active Expired - Lifetime
-
1993
- 1993-08-02 AU AU47903/93A patent/AU688735B2/en not_active Ceased
- 1993-08-02 JP JP6505415A patent/JP2892838B2/ja not_active Expired - Lifetime
- 1993-08-02 PL PL93307309A patent/PL307309A1/xx unknown
- 1993-08-02 EP EP93918463A patent/EP0654027A1/en not_active Withdrawn
- 1993-08-02 SK SK131-95A patent/SK13195A3/sk unknown
- 1993-08-02 HU HU9500349A patent/HU9500349D0/hu unknown
- 1993-08-02 IL IL106553A patent/IL106553A0/xx unknown
- 1993-08-02 BR BR9306911A patent/BR9306911A/pt not_active Application Discontinuation
- 1993-08-02 WO PCT/US1993/007103 patent/WO1994003435A1/en not_active Application Discontinuation
- 1993-08-02 SG SG1996008109A patent/SG47108A1/en unknown
- 1993-08-02 FI FI950485A patent/FI950485A7/fi not_active Application Discontinuation
- 1993-08-02 CA CA002141692A patent/CA2141692C/en not_active Expired - Lifetime
- 1993-08-05 ZA ZA935693A patent/ZA935693B/xx unknown
- 1993-08-06 MX MX9304787A patent/MX9304787A/es unknown
- 1993-08-06 TW TW082106302A patent/TW239131B/zh active
- 1993-08-06 CN CN93117634A patent/CN1090275A/zh active Pending
-
1995
- 1995-02-03 NO NO950404A patent/NO950404D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX9304787A (es) | 1995-01-31 |
| US5310929A (en) | 1994-05-10 |
| CA2141692C (en) | 2006-05-30 |
| PL307309A1 (en) | 1995-05-15 |
| HU9500349D0 (en) | 1995-03-28 |
| WO1994003435A1 (en) | 1994-02-17 |
| FI950485L (fi) | 1995-02-03 |
| CA2141692A1 (en) | 1994-02-17 |
| FI950485A0 (fi) | 1995-02-03 |
| SK13195A3 (en) | 1995-07-11 |
| JP2892838B2 (ja) | 1999-05-17 |
| ZA935693B (en) | 1995-02-06 |
| AU4790393A (en) | 1994-03-03 |
| CN1090275A (zh) | 1994-08-03 |
| FI950485A7 (fi) | 1995-02-03 |
| BR9306911A (pt) | 1998-12-08 |
| EP0654027A1 (en) | 1995-05-24 |
| NO950404D0 (no) | 1995-02-03 |
| IL106553A0 (en) | 1993-12-08 |
| SG47108A1 (en) | 1998-03-20 |
| JPH08500103A (ja) | 1996-01-09 |
| AU688735B2 (en) | 1998-03-19 |